Novosanis receives grant from Interreg CrossCare to build a next-generation of its unique and patented intradermal drug delivery device, VAX-ID, in collaboration with living labs Happy Aging (Belgium) and CIC (the Netherlands).
Intradermal delivery has several advantages to traditional delivery solutions, where products are typically injected into muscle or fat. The dermal layer of the skin contains higher number of immune cells, allowing targeted drug delivery as well as offering dose-sparing capacity (Lambert et. al, 2008; Weniger et. al, 2012).
However, current intradermal injection systems, such as the Mantoux technique have limitations. The procedure is painful, requires extensive training and lacks accuracy (WHO, 2014).
Contrastingly, VAX-ID offers accurate penetration depth and volume delivery. The device is painless, semi-customizable, and easy-to-use, even independently, offering a range of applications, especially in areas where training is difficult (Van Mulder et. al, 2014).
The primary goal of the CrossCare grant is to allow Novosanis to evaluate a next-generation of the device with improved functionality and usability. The project also aims to gain feedback from end-users through co-creation sessions and usability testing of 3D-printed prototypes. The new version will be suited for large scale manufacturing and allow for higher marketability for different applications, including vaccination and immunotherapy.
The project is financed via the framework CrossCare from the European Interreg Flanders-Netherlands program (www.grensregio.eu). Interreg Vlaanderen-Nederland promotes cross-border projects for smart, green and inclusive growth, from the European Regional Development Fund (ERDF).
Learn more about VAX-ID here: https://novosanis.com/delivery-solutions
1. Lambert PH, et al. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Review article. Vaccine. 2008
2. Weniger BG, Papania MJ. Alternative vaccine delivery methods. Philadelpia: Saunders In: Plotkin SA, Orenstein WA, Offit PA, editors. Six ed Vaccines (Elsevier; ). 2012. 1200-31.
3. Van Mulder TJ, Verwulgen S, Beyers KC, Scheelen L, Elseviers MM, Van Damme P, Vankerckhoven V. Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects. Hum Vaccines & Immunotherapeutics. 2014
4. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. World Health Organization. 2014.